Healthcare Industry News: ESTECH
News Release - June 7, 2006
Neoprobe and ESTECH Announce Distribution AgreementESTECH to Distribute Quantix Blood Flow Devices in U.S.
DUBLIN, Ohio--(HSMN NewsFeed)--June 7, 2006--Neoprobe Corporation (OTCBB:NEOP ), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has entered into a national distribution agreement with ESTECH, Inc. (privately held) of Danville, CA, for distribution in the U.S. of the Quantix/OR blood flow measurement system. The Quantix/OR is designed to provide surgeons with quantitative hemodynamic information in coronary artery bypass graft (CABG) and carotid endarterectomy procedures.
"We believe that this agreement is an important step in our continuing effort to provide physicians with innovative new technologies for improving cardiac surgery outcomes," said Ray Bertolero, ESTECH Vice President and co-founder. "The Quantix/OR system complements our current offerings for cardiovascular surgery and provides us with a unique opportunity to expand our product offering for cardiovascular surgery in the U.S. market."
"The ESTECH agreement provides us with a proven national marketing organization and validates our belief in the blood flow measurement market," said David Bupp, President of Neoprobe. "By joining a leader in servicing the CABG marketplace, the Quantix/OR system will be better positioned to achieve broader market penetration. The strength of ESTECH's product offering will allow us to establish a strong presence in the key market for our blood flow products."
ESTECH headquartered in San Ramon, CA offers tools for least invasive techniques and traditional approaches to the procedures that cardiac surgeons do every day - coronary artery bypass, valve surgery, atrial ablation and surgical treatment of congestive heart failure.
Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons for intraoperative lymphatic mapping and the Quantix® line of blood flow measurement products that are designed to be used by cardiovascular surgeons, neurosurgeons and critical care physicians. In addition, Neoprobe holds significant interests in the development of related biomedical systems and agents including Lymphoseek(TM) and RIGScan® CR. Lymphoseek is an investigational drug being developed as a lymphatic tracing agent. The RIGS® system is an investigational technology that combines the Company's gamma detection device technology with a proprietary disease-specific radiolabeled cancer targeting agent that is injected into a cancer patient prior to their surgery, and a patented surgical method to get real-time information to locate tumor deposits that may not be detectable by conventional methods. www.neoprobe.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.